| Literature DB >> 30644100 |
Jing Zhu1, Tailang Yin2, Yong Xu3, Xiao-Jie Lu1.
Abstract
Hepatocellular carcinoma (HCC) is one of the most common malignancies and is a serious threat to people's health worldwide. The prognosis of advanced HCC is dim if left untreated. In the clinic, the treatment options for advanced HCC include surgery, radiotherapy, transcatheter arterial chemoembolization, and so forth. In recent years, molecular targeted therapy and immunotherapy have also made great progress, bringing new hope to patients with advanced HCC. In this study, therapeutic advances, current dilemma, and future directions of advanced HCC are reviewed, which might serve as a summary for clinicians and may stimulate future research.Entities:
Keywords: Hepatocellular carcinoma (HCC); portal vein tumor thrombosis; transcatheter arterial chemoembolization: immunotherapy
Mesh：
Substances：
Year: 2019 PMID： 30644100 DOI： 10.1002/jcp.28048
Source DB: PubMed Journal: J Cell Physiol ISSN： 0021-9541 Impact factor: 6.384